Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. The Company uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors. The product candidates in its pipeline are categorized into three groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumour inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Its advanced product candidate is vebreltinib (APL-101), a potent, oral active, highly selective c-Met inhibitor. Its anti-cancer enhancer product candidates include uproleselan (APL-106) and are antagonists of a cell adhesion receptor called E-selectin. Its immuno-oncology product candidates consist of APL-501, APL-502, APL-801 and APL-810. Its other product candidates include APL-122, APL-102, and APL-108.
